SAN CLEMENTE, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ICU Medical, (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the J.P. Morgan 41st Annual Healthcare Conference, being held in San Francisco, CA, January 9-12, 2023. ICU Medical’s presentation will be on Wednesday, January 11, 2023 at 1:30 p.m. PST (4:30 p.m. EST).
The presentation will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will also be available by replay.
About ICU Medical
ICU Medical (Nasdaq:ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com
CONTACT:
ICU Medical, Inc.
Brian Bonnell, Chief Financial Officer
(949) 366-2183
ICR, Inc.
John Mills, Managing Partner
(646) 277-1254

| Last Trade: | US$146.22 |
| Daily Change: | -2.22 -1.50 |
| Daily Volume: | 104,366 |
| Market Cap: | US$3.610B |
November 06, 2025 August 07, 2025 April 07, 2025 February 27, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load